Treatment of congenital nevi with the Q-switched Alexandrite laser.

Q-switched mode lasers have been utilized for treatment of many pigmentary lesions. Because of their short pulse durations (1-100 ns), these lasers selectively destroy pigment laden cells while sparing the surrounding normal tissues. To determine if the Q-switched alexandrite laser (QSAL) is effective in the treatment of congenital melanocytic nevi, 53 patients with these lesions were treated with QSAL; of these, 16 also received CO(2) laser treatment between QSAL treatments. We observed an average improvement score in the 53 treated patients of 2.623 + 1.13, corresponding to a 72% improvement. Treatment with the combination of QSAL and a CO(2) laser resulted in a significant enhancement of improvement score (3.06 +/- 1.18) compared to patients treated with the QSAL alone (2.43 +/- 1.07; p = 0.0393). Complications were mild, with 35 nevi (67.3%) showing textural change of skin after treatment, 2 (3.8%) showing depressed scar formation, and 4 (7.5%) showing hypertrophic changes, while 12 nevi (23%) showed no changes. Hypopigmentation was observed in 16 patients (30%), and hyperpigmentation was observed in 15 patients (28%) 48 weeks after the final QSAL treatment. Repigmentation to a brown to black spot was observed in 44/53 (83%) patients within an average of 5.45 +/- 3.93 months. These results indicate that the QSAL was as effective as other Q switch mode lasers in the treatment of congenital melanocytic nevi, but repigmentation is a problem.
AuthorsSangeun Kim, Won Hyoung Kang
JournalEuropean journal of dermatology : EJD (Eur J Dermatol) 2005 Mar-Apr Vol. 15 Issue 2 Pg. 92-6 ISSN: 1167-1122 [Print] France
PMID15757819 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Laser Therapy (methods)
  • Male
  • Middle Aged
  • Nevus, Pigmented (congenital, pathology, surgery)
  • Retrospective Studies
  • Skin Neoplasms (congenital, pathology, surgery)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: